Sole Dealer Manager to TriSalus Life Sciences, Inc.

Oppenheimer & Co. Inc. acted as Sole Dealer Manager to TriSalus Life Sciences Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI) on its warrant exchange of 7,038,299 public and private warrants, issuing 2,110,366 shares of the Company’s common stock in exchange for the warrants tendered in the offer.

TriSalus launched a public exchange offer and concurrent solicitation for its outstanding warrants on May 24, 2024. Prior to transaction launch, Oppenheimer ran a fully confidential process, targeting top holders of the public warrants to negotiate an exchange ratio that de-risked the offering. During the wall cross process, Oppenheimer was able to secure 38.3% support from existing public warrant holders via executed support agreements. Upon public announcement, the Company was required to provide 20-business days for all holders to consider the exchange offer. Following conclusion of the tender period, 78.9% of the public warrants were tendered and exchanged for common shares on July 1, 2024. Given participation by public warrant holders exceeded the 50.0% warrant consent threshold, the Company is permitted to require each public warrant that remains outstanding upon the closing of the offer to be converted into shares of common stock at a ratio 10% less than the exchange ratio applicable to the offer.

TriSalus Life Sciences is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy.